专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20130029902A1 CXC CHEMOKINE RECEPTOR 4 (CXCR4) ANTAGONISTIC POLYPEPTIDE 有权
标题翻译： CXC CHEMOKINE RECEPTOR 4（CXCR4）ANTAGONISTIC POLYPEPTIDE
公开(公告)号：US20130029902A1
公开(公告)日：2013-01-31
申请号：US12452480
申请日：2008-07-03
申请人： Wolf-Georg Forssmann , Frank Kirchhoff , Jan Münch , Ludger Ständker
发明人： Wolf-Georg Forssmann , Frank Kirchhoff , Jan Münch , Ludger Ständker
IPC分类号： A61K38/10 , C07K7/08 , C12N15/12 , C12N15/63 , C07K16/18 , A61K38/08 , A61K31/7088 , C07K1/18 , C07K1/04 , C12P21/02 , A61P31/12 , A61P31/18 , A61P31/22 , A61P31/14 , A61P31/16 , A61P31/04 , A61P31/10 , A61P29/00 , A61P7/04 , A61P25/00 , A61P35/00 , A61P17/02 , A61P19/00 , C12N1/00 , H01J49/26 , C07K7/06
CPC分类号： C07K14/765 , A61K38/00 , G01N2333/715 , Y02A50/463 , Y02A50/465
摘要： A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.
摘要翻译：具有以下氨基酸序列的肽：Z1-LVRYTKKVPQVSTPTL-Z2（ALB-408）及其生物活性片段和/或变体和/或衍生物，特别是酰胺化的，乙酰化的，硫酸化的，磷酸化的和/或糖基化的衍生物，以及可获得的肽通过具有ALB408-423生物活性的多重合成; 其中Z表示0至10个氨基酸残基的数目。

72. 发明申请

US20120244069A1 HUMAN MONOCLONAL ANTIBODIES AGAINST CD25 有权
标题翻译：人类单克隆抗体CD25
公开(公告)号：US20120244069A1
公开(公告)日：2012-09-27
申请号：US13465181
申请日：2012-05-07
申请人： Janine SCHUURMAN , Catharina Emanuele Gerarda HAVENITH , Paul PARREN , Jan G. J. VAN DE WINKEL , Denise Leah WILLIAMS , Jørgen PETERSEN , Ole BAADSGAARD
发明人： Janine SCHUURMAN , Catharina Emanuele Gerarda HAVENITH , Paul PARREN , Jan G. J. VAN DE WINKEL , Denise Leah WILLIAMS , Jørgen PETERSEN , Ole BAADSGAARD
IPC分类号： A61K39/395 , A61K51/10 , C07K16/28 , A61P19/02 , A61P3/10 , A61N5/06 , A61P21/04 , A61P1/00 , A61P1/04 , A61P11/06 , G01N33/577 , A61M37/00 , C07K17/00 , A61P25/00
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/062 , C07K16/4258 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/56966 , G01N33/57492 , G01N33/6854 , G01N33/6869 , G01N2333/70596 , G01N2333/715 , G01N2333/7155
摘要： Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
摘要翻译：公开了结合并抑制人CD25的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人类转基因动物例如转基因小鼠产生。还公开了包含人抗体，非人转基因动物，产生人抗体的杂交瘤和转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

73. 发明申请

US20120208717A1 Systems and methods for characterizing kidney diseases 有权
标题翻译：表征肾脏疾病的系统和方法
公开(公告)号：US20120208717A1
公开(公告)日：2012-08-16
申请号：US13452569
申请日：2012-04-20
申请人： Huaizhong Hu , Stuart Knechtle
发明人： Huaizhong Hu , Stuart Knechtle
IPC分类号： C40B30/04 , G01N33/53
CPC分类号： G01N33/6863 , G01N33/57442 , G01N33/6893 , G01N2333/522 , G01N2333/70578 , G01N2333/715 , G01N2800/245 , G01N2800/347 , G01N2800/60
摘要： The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.
摘要翻译：本发明涉及诊断，预测和监测肾脏疾病的方法。特别地，本发明涉及通过检测尿中细胞因子，细胞因子相关化合物和趋化因子来诊断，预测和监测肾脏疾病。本发明还涉及用于评估用于治疗肾脏疾病的药剂和干预措施的功效的方法和组合物。

74. 发明申请

US20110256555A1 USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL 审中-公开
标题翻译： CXCR4蛋白表达在干细胞表面上的应用作为肿瘤热点潜力的标记
公开(公告)号：US20110256555A1
公开(公告)日：2011-10-20
申请号：US13163553
申请日：2011-06-17
申请人： John S. Yu , Moneeb Ehtesham
发明人： John S. Yu , Moneeb Ehtesham
IPC分类号： C12Q1/02 , G01N33/53
CPC分类号： C12N5/0623 , C12N2501/11 , C12N2501/115 , G01N33/5017 , G01N33/5073 , G01N2333/715
摘要： The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1.
摘要翻译：本发明涉及肿瘤热带干细胞，特别涉及神经干细胞，以及它们作为治疗性基因产物转移至肿瘤灶的递送载体的用途。基于显示CXCR4受体的干细胞或对趋化因子SDF-1的亲和力，选择具有肿瘤嗜性潜能的干细胞。干细胞可能另外表现出星形细胞祖细胞特征的标志物。干细胞可以作为治疗方案的一部分施用，包括趋化因子SDF-1。

75. 发明授权

US08030005B2 Method for detecting antigen specific or mitogen-activated T cells 有权
标题翻译：检测抗原特异性或丝裂原活化T细胞的方法
公开(公告)号：US08030005B2
公开(公告)日：2011-10-04
申请号：US12293222
申请日：2007-03-20
申请人： Anthony Dominic Kelleher , John James Zaunders
发明人： Anthony Dominic Kelleher , John James Zaunders
IPC分类号： G01N33/53
CPC分类号： G01N33/56972 , G01N2333/70514 , G01N2333/70517 , G01N2333/70578 , G01N2333/70596 , G01N2333/715
摘要： The present invention comprises a method for the quantitative or qualitative detection of antigen-specific CD4+ T cells and/or CD8+ T cells in a subject, said method comprising quantitatively or qualitatively detecting the expression of cell surface marker CD25 and one or more of cell surface markers CD134 and CD137 in a suitable lymphocyte-containing sample from said subject in response to exposure to an antigen. A method for determining the immunocompetence of a subject and a method for isolating antigen-specific CD4+ and/or CD8+ T cells is also disclosed.
摘要翻译：本发明包括用于定量或定性检测受试者中抗原特异性CD4 + T细胞和/或CD8 + T细胞的方法，所述方法包括定量或定性检测细胞表面标志物CD25和细胞表面的一种或多种的表达标记CD134和CD137在来自所述受试者的适合的含淋巴细胞的样品中以响应于暴露于抗原。还公开了用于确定受试者的免疫活性的方法和分离抗原特异性CD4 +和/或CD8 + T细胞的方法。

76. 发明授权

US07803557B2 Methods for identification of eicosapentaenoic acid analogs using anti-inflammatory receptors 有权
标题翻译：使用抗炎症受体鉴定二十碳五烯酸类似物的方法
公开(公告)号：US07803557B2
公开(公告)日：2010-09-28
申请号：US12045427
申请日：2008-03-10
申请人： Charles N. Serhan , Makoto Arita
发明人： Charles N. Serhan , Makoto Arita
IPC分类号： G01N33/53 , G01N33/567
CPC分类号： G01N33/5047 , G01N33/5023 , G01N33/5032 , G01N33/5041 , G01N33/505 , G01N33/566 , G01N2333/4703 , G01N2333/715 , G01N2333/726 , G01N2500/04
摘要： The present invention is directed to methods for the identification and uses of a receptors that interact with anti-inflammatory compounds derived from eicosapentaenoic acid (EPA). The receptors are of the G-protein coupled receptor (GPCR) family, and are useful to screen candidate substances for anti-inflammatory activity, especially substances that are analogs of EPA. Such analogs are termed “resolvins”; and are typically di- and tri-hydroxy EPA analogs. One analog herein denoted Resolvin E1 was identified in humans and prepared by total synthesis. In nanomolar range Resolvin E1 reduces dermal inflammation, peritonitis, dendritic cells (DCs) migration and IL-12 production. Also described herein is a receptor denoted Reso ER1 that interacts with Resolvin E1 to attenuate cytokine induced activation of inflammatory pathways mediated by transcription factor (NF)-kB. Treatment of DCs with small-interfering RNA specific for ResoE1 eliminated the ligand's ability to regulate IL-12. Assays of anti-inflammatory activity based on these discoveries are also described.
摘要翻译：本发明涉及鉴定和使用与二十碳五烯酸（EPA）衍生的抗炎化合物相互作用的受体的方法。受体是G蛋白偶联受体（GPCR）家族，可用于筛选候选物质的抗炎活性，特别是类似于EPA的物质。这样的类似物被称为“溶解素”; 并且通常是二羟基和三羟基EPA类似物。在人类中鉴定了一种在本文中称为Resolvin E1的类似物，并通过全合成制备。在纳摩尔范围内，Resolvin E1可减少皮肤炎症，腹膜炎，树突细胞（DCs）迁移和IL-12的产生。本文还描述了称为Reso ER1的受体，其与Resolvin E1相互作用以减弱由转录因子（NF）-kB介导的炎症途径的细胞因子诱导的活化。用特异于ResoE1的小干扰RNA处理DC消除了配体调节IL-12的能力。还描述了基于这些发现的抗炎活性测定。

77. 发明授权

US07341840B2 Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs 有权
标题翻译：用于二十碳五烯酸类似物的抗炎症受体的鉴定和使用方法
公开(公告)号：US07341840B2
公开(公告)日：2008-03-11
申请号：US11218281
申请日：2005-09-01
申请人： Charles N. Serhan , Makoto Arita
发明人： Charles N. Serhan , Makoto Arita
IPC分类号： G01N33/53 , G01N33/567
CPC分类号： G01N33/5047 , G01N33/5023 , G01N33/5032 , G01N33/5041 , G01N33/505 , G01N33/566 , G01N2333/4703 , G01N2333/715 , G01N2333/726 , G01N2500/04
摘要： The present invention is directed to methods for the identification and uses of receptors that interact with anti-inflammatory compounds derived from eicosapentaenoic acid (EPA). The receptors are of the G-protein coupled receptor (GPCR) family, and are useful to screen candidate substances for anti-inflammatory activity, especially substances that are analogs of EPA. Such analogs are termed “resolvins”; and are typically di- and tri-hydroxy EPA analogs. One analog herein denoted Resolvin E1 was identified in humans and prepared by total synthesis. In nanomolar range Resolvin E1 reduces dermal inflammation, peritonitis, dendritic cells (DCs) migration and IL-12 production. Also described herein is a receptor denoted Reso ER1 that interacts with Resolvin E1 to attenuate cytokine induced activation of inflammatory pathways mediated by transcription factor (NF)-kB. Treatment of DCs with small-interfering RNA specific for ResoE1 eliminated the ligand's ability to regulate IL-12. Assays of anti-inflammatory activity based on these discoveries are also described.
摘要翻译：本发明涉及鉴定和使用与二十碳五烯酸（EPA）衍生的抗炎化合物相互作用的受体的方法。受体是G蛋白偶联受体（GPCR）家族，可用于筛选候选物质的抗炎活性，特别是类似于EPA的物质。这样的类似物被称为“溶解素”; 并且通常是二羟基和三羟基EPA类似物。在人类中鉴定了一种在本文中称为Resolvin E1的类似物，并通过全合成制备。在纳摩尔范围内，Resolvin E1可减少皮肤炎症，腹膜炎，树突细胞（DCs）迁移和IL-12的产生。本文还描述了称为Reso ER1的受体，其与Resolvin E1相互作用以减弱由转录因子（NF）-kB介导的炎症途径的细胞因子诱导的活化。用特异于ResoE1的小干扰RNA处理DC消除了配体调节IL-12的能力。还描述了基于这些发现的抗炎活性测定。

78. 发明申请

US20070015228A1 Assay for Antibodies 审中-公开
标题翻译：抗体测定
公开(公告)号：US20070015228A1
公开(公告)日：2007-01-18
申请号：US11535422
申请日：2006-09-26
申请人： Anan Chuntharapai , Kyu Hong , Yu-Ju Meng
发明人： Anan Chuntharapai , Kyu Hong , Yu-Ju Meng
IPC分类号： G01N33/53 , C07K16/18 , C12N5/06
CPC分类号： C07K16/4258 , C07K16/2896 , C07K2317/24 , C07K2317/55 , C07K2317/92 , G01N33/686 , G01N2333/70532 , G01N2333/70578 , G01N2333/70596 , G01N2333/715 , G01N2333/726
摘要： The presence and quantity of an antibody of interest in a patient's bloodstream or other biological sample can serve as an important clinical or other analytical or diagnostic tool. ELISA methods, and kits for such assays, as well as anti-idiotypic antibodies and hybridomas producing them, are developed to detect levels of the antibody in biological samples, which are from, for example, animal models and human patients.
摘要翻译：患者血液或其他生物样品中目标抗体的存在和数量可作为重要的临床或其他分析或诊断工具。开发了ELISA方法和用于这种测定的试剂盒，以及抗独特型抗体和产生它们的杂交瘤，以检测来自例如动物模型和人类患者的生物样品中抗体的水平。

79. 发明申请

US20070003545A9 Interleukin-8 homologous polypeptides and therapeutic uses thereof 审中-公开
公开(公告)号：US20070003545A9
公开(公告)日：2007-01-04
申请号：US10886040
申请日：2004-07-08
申请人： Dan Eaton , Maria Pisabarro , Kerstin Schmidt , Richard Vandlen , Nancy Chiang , Lauri Diehl
发明人： Dan Eaton , Maria Pisabarro , Kerstin Schmidt , Richard Vandlen , Nancy Chiang , Lauri Diehl
IPC分类号： G01N33/53 , A61K39/395 , C12N5/06 , C07K16/44 , C07K16/18
CPC分类号： G01N33/57449 , C07K14/5421 , C07K16/24 , C07K2317/76 , G01N33/57415 , G01N33/57442 , G01N33/57496 , G01N33/576 , G01N33/6869 , G01N2333/715 , G01N2800/08 , G01N2800/085 , G01N2800/24
摘要： The present invention is directed to novel polypeptides having structural homology to IL-8 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treatment and diagnosis of inflammatory diseases.

80. 发明申请

US20060257410A1 Reagents that bind CCX-CKR2 有权
标题翻译：绑定CCX-CKR2的试剂
公开(公告)号：US20060257410A1
公开(公告)日：2006-11-16
申请号：US11407729
申请日：2006-04-19
申请人： Maureen Howard , Thomas Schall
发明人： Maureen Howard , Thomas Schall
IPC分类号： A61K39/395 , G01N33/574
CPC分类号： C07K16/2866 , G01N33/6863 , G01N2333/715 , G01N2500/10
摘要： Antibodies that bind to CCX-CKR2 and methods of their use are provided.
摘要翻译：提供了结合CCX-CKR2的抗体及其使用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式